Search - tctmd.com

Displaying 1 - 11 of 11

Sort: Relevancy | Date

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

News Conference News VIVA 2024

Amputations Still Avoided With Flow-Diverting Therapy for CLTI at 2 Years: PROMISE II

November 06, 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

News Conference News VIVA 2024

Disappearing Scaffold for CLTI Still Works Well at 2 Years: LIFE-BTK

November 05, 2024

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

News Conference News VIVA 2022

‘Heartless’ Indifference Drives PAD/CLTI Amputations in Underserved Groups

November 04, 2022

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

News Conference News VIVA 2021

Striking Racial Gaps Exist in Care for Peripheral Interventions, Registry Affirms

October 07, 2021

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

News Conference News VIVA 2021

Vascular Care Falls Short Before Amputation for CLI: Medicare Analysis

October 06, 2021

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

News Conference News VIVA 2020

BVS Reboot? Signs of Durability to 2 Years in Critical Limb-Threatening Ischemia

November 11, 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

News Conference News VIVA 2020

DISRUPT PAD III: Lithotripsy Shows Promise in Heavily Calcified PAD

November 09, 2020

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

November 05, 2019

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

News Conference News VIVA 2018

Consulting the COMPASS for Rivaroxaban’s Role in Peripheral Vascular Disease

November 15, 2018

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

News Conference News VIVA 2017

Low-Dose Paclitaxel DCB Shows Long-term Durability in Treating PAD

September 18, 2017

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

News Conference News VIVA 2016

Positive Results Continue at 2 Years for Paclitaxel-Eluting PAD Stent

September 20, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.